Aaron Schimmer - Publications

Affiliations: 
Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Cell Biology, Molecular Biology, Oncology

195 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, ... ... Schimmer AD, et al. The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids. Cell Stem Cell. 24: 1007. PMID 31173706 DOI: 10.1016/j.stem.2019.04.020  0.36
2019 Ishizawa J, Zarabi SF, Davis RE, Halgas O, Nii T, Jitkova Y, Zhao R, St-Germain J, Heese LE, Egan G, Ruvolo VR, Barghout SH, Nishida Y, Hurren R, Ma W, ... ... Schimmer AD, et al. Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell Lethality. Cancer Cell. PMID 31056398 DOI: 10.1016/j.ccell.2019.03.014  0.36
2019 Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, ... ... Schimmer AD, et al. The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids. Cell Stem Cell. PMID 30930145 DOI: 10.1016/j.stem.2019.02.020  0.36
2018 Yehudai D, Liyanage SU, Hurren R, Rizoska B, Albertella M, Gronda M, Jeyaraju DV, Wang X, Barghout SH, MacLean N, Siriwardena TP, Jitkova Y, Targett-Adams P, Schimmer AD. The thymidine dideoxynucleoside analogue, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia. Haematologica. PMID 30573504 DOI: 10.3324/haematol.2018.195172  0.36
2018 Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, Zarabi SF, Gronda M, Hurren R, Jeyaraju DV, MacLean N, Brennan S, Hyer ML, Berger A, Traore T, ... ... Schimmer AD, et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. Leukemia. PMID 29884901 DOI: 10.1038/s41375-018-0167-0  0.36
2018 Kavanagh S, Heath E, Hurren R, Gronda M, Barghout SH, Liyanage SU, Siriwardena TP, Claudio J, Zhang T, Sukhai M, Stockley TL, Kamel-Reid S, Rostom A, Lutynski A, Khalaf D, ... ... Schimmer AD, et al. AML refractory to primary induction with Ida-FLAG has a poor clinical outcome. Leukemia Research. 68: 22-28. PMID 29518628 DOI: 10.1016/j.leukres.2018.02.012  0.36
2017 Liyanage SU, Hurren R, Voisin V, Bridon G, Wang X, Xu C, MacLean N, Siriwardena TP, Gronda M, Yehudai D, Sriskanthadevan S, Avizonis D, Shamas-Din A, Minden MD, Bader GD, ... ... Schimmer AD, et al. Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. Blood. PMID 28283480 DOI: 10.1182/blood-2016-10-741207  0.36
2016 Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD. A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Medicine. PMID 27734609 DOI: 10.1002/cam4.845  0.36
2016 Rotin LE, MacLean N, Aman A, Gronda M, Lin FH, Hurren R, Wang X, Wrana JL, Datti A, Al-Awar R, Minden MD, Schimmer AD. Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells. Haematologica. PMID 27587383 DOI: 10.3324/haematol.2016.146894  0.36
2016 Jones RA, Robinson TJ, Liu JC, Shrestha M, Voisin V, Ju Y, Chung PE, Pellecchia G, Fell VL, Bae S, Muthuswamy L, Datti A, Egan SE, Jiang Z, Leone G, ... ... Schimmer A, et al. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. The Journal of Clinical Investigation. PMID 27571409 DOI: 10.1172/JCI81568  0.8
2016 Sibai H, Seki JT, Wang TQ, Sakurai N, Atenafu EG, Yee KW, Schuh AC, Gupta V, Minden MD, Schimmer AD, Brandwein JM. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia. Current Oncology (Toronto, Ont.). 23: e355-61. PMID 27536184 DOI: 10.3747/co.23.3077  0.8
2016 Jeyaraju DV, Hurren R, Wang X, MacLean N, Gronda M, Shamas-Din A, Minden MD, Giaever G, Schimmer AD. A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia. Oncotarget. PMID 27391350 DOI: 10.18632/oncotarget.10446  0.8
2016 Zhang Z, Tong J, Tang X, Juan J, Cao B, Hurren R, Chen G, Taylor P, Xu X, Shi CX, Du J, Hou J, Wang G, Wu D, Stewart AK, ... Schimmer AD, et al. The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. Blood. PMID 26825710 DOI: 10.1182/blood-2015-07-658203  0.8
2016 Hedley D, Shamas-Din A, Chow S, Sanfelice D, Schuh AC, Brandwein JM, Seftel MD, Gupta V, Yee KW, Schimmer AD. A Phase I Study of Elesclomol Sodium in Patients with Acute Myeloid Leukemia. Leukemia & Lymphoma. 1-13. PMID 26732437 DOI: 10.3109/10428194.2016.1138293  0.8
2016 Rotin LE, Gronda M, Hurren R, Wang XM, Minden MD, Slassi M, Schimmer AD. Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells. Leukemia & Lymphoma. 1-11. PMID 26732203 DOI: 10.3109/10428194.2016.1138292  0.8
2015 Gao C, Leyton JV, Schimmer AD, Minden M, Reilly RM. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells. Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 110: 1-7. PMID 26748017 DOI: 10.1016/j.apradiso.2015.12.043  0.8
2015 Rotin LE, Gronda M, MacLean N, Hurren R, Wang X, Lin FH, Wrana J, Datti A, Barber DL, Minden MD, Slassi M, Schimmer AD. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism. Oncotarget. PMID 26624983 DOI: 10.18632/oncotarget.6409  0.36
2015 Deotare U, Yee KW, Le LW, Porwit A, Tierens A, Musani R, Barth D, Torlakovic E, Schimmer A, Schuh AC, Seftel M, Minden MD, Gupta V, Hyjek E. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-colour flow cytometry diagnosis and HyperCVAD therapy. American Journal of Hematology. PMID 26619305 DOI: 10.1002/ajh.24258  0.8
2015 Bartoszko J, Panzarella T, Lau A, Schimmer A, Schuh A, Shanavas M, Yee K, Gupta V. Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. Clinical Lymphoma, Myeloma & Leukemia. 15: e151-6. PMID 26566925 DOI: 10.1016/j.clml.2015.09.001  0.8
2015 Bralha FN, Liyanage SU, Hurren R, Wang X, Son MH, Fung TA, Chingcuanco FB, Tung AY, Andreazza AC, Psarianos P, Schimmer AD, Salmena L, Laposa RR. Targeting mitochondrial RNA polymerase in acute myeloid leukemia. Oncotarget. 6: 37216-28. PMID 26484416 DOI: 10.18632/oncotarget.6129  0.8
2015 Gheihman G, Zimmermann C, Deckert A, Fitzgerald P, Mischitelle A, Rydall A, Schimmer A, Gagliese L, Lo C, Rodin G. Depression and hopelessness in patients with acute leukemia: the psychological impact of an acute and life-threatening disorder. Psycho-Oncology. PMID 26383625 DOI: 10.1002/pon.3940  0.8
2015 Nirmalanandhan VS, Hurren R, Cameron WD, Gronda M, Shamas-Din A, You L, Minden MD, Rocheleau JV, Schimmer AD. Increased pressure alters plasma membrane dynamics and renders acute myeloid leukemia cells resistant to daunorubicin. Haematologica. PMID 26185171 DOI: 10.3324/haematol.2015.129866  0.8
2015 Wang Z, Dove P, Wang X, Shamas-Din A, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, Press B, Griffin C, Undzys E, Aman A, Al-Awar R, ... ... Schimmer AD, et al. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. Cell Death & Disease. 6: e1815. PMID 26158521 DOI: 10.1038/cddis.2015.187  0.8
2015 Lee EA, Angka L, Rota SG, Hanlon T, Mitchell A, Hurren R, Wang XM, Gronda M, Boyaci E, Bojko B, Minden M, Sriskanthadevan S, Datti A, Wrana JL, Edginton A, ... ... Schimmer AD, et al. Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death. Cancer Research. 75: 2478-88. PMID 26077472 DOI: 10.1158/0008-5472.CAN-14-2676  0.8
2015 Cole A, Wang Z, Coyaud E, Voisin V, Gronda M, Jitkova Y, Mattson R, Hurren R, Babovic S, Maclean N, Restall I, Wang X, Jeyaraju DV, Sukhai MA, Prabha S, ... ... Schimmer AD, et al. Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia. Cancer Cell. 27: 864-76. PMID 26058080 DOI: 10.1016/j.ccell.2015.05.004  0.8
2015 Jean SR, Tulumello DV, Riganti C, Liyanage SU, Schimmer AD, Kelley SO. Mitochondrial Targeting of Doxorubicin Eliminates Nuclear Effects Associated with Cardiotoxicity. Acs Chemical Biology. 10: 2007-15. PMID 26038829 DOI: 10.1021/acschembio.5b00268  0.8
2015 Wu Y, Hurren R, MacLean N, Gronda M, Jitkova Y, Sukhai MA, Minden MD, Schimmer AD. Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis : An International Journal On Programmed Cell Death. 20: 1099-108. PMID 25998464 DOI: 10.1007/s10495-015-1137-x  0.36
2015 Shamas-Din A, Schimmer AD. Drug discovery in academia. Experimental Hematology. 43: 713-7. PMID 25912018 DOI: 10.1016/j.exphem.2015.02.007  0.8
2015 Bernard D, Gebbia M, Prabha S, Gronda M, MacLean N, Wang X, Hurren R, Sukhai MA, Cho EE, Manolson MF, Datti A, Wrana J, Minden MD, Al-Awar R, Aman A, ... ... Schimmer AD, et al. Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells. Apoptosis : An International Journal On Programmed Cell Death. 20: 948-59. PMID 25832785 DOI: 10.1007/s10495-015-1123-3  0.8
2015 Yeung M, Hurren R, Nemr C, Wang X, Hershenfeld S, Gronda M, Liyanage S, Wu Y, Augustine J, Lee EA, Spagnuolo PA, Southall N, Chen C, Zheng W, Jeyaraju DV, ... ... Schimmer AD, et al. Mitochondrial DNA damage by bleomycin induces AML cell death. Apoptosis : An International Journal On Programmed Cell Death. 20: 811-20. PMID 25820141 DOI: 10.1007/s10495-015-1119-z  0.8
2015 How J, Minden MD, Brian L, Chen EX, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Webster S, Degelder T, Haines P, Stayner LA, McGill S, Wang L, Piekarz R, et al. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. Leukemia & Lymphoma. 1-10. PMID 25682963 DOI: 10.3109/10428194.2015.1018248  0.8
2015 Hillis CM, Schimmer AD, Couban S, Crowther MA. The Canadian Choosing Wisely campaign: the Canadian Hematology Society's top five tests and treatments. Annals of Hematology. 94: 541-5. PMID 25637447 DOI: 10.1007/s00277-015-2304-4  0.8
2015 Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W, Skrtic M, Jhas B, Hurren R, Gronda M, Wang X, Jitkova Y, Sukhai MA, Lin FH, Maclean N, Laister R, ... ... Schimmer AD, et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood. 125: 2120-30. PMID 25631767 DOI: 10.1182/blood-2014-08-594408  0.8
2015 Kuo KH, Callum JL, Panzarella T, Jacks LM, Brandwein J, Crump M, Curtis JE, Gupta V, Lipton JH, Minden MD, Sher GD, Schimmer AD, Schuh AC, Yee KW, Keating A, et al. A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. British Journal of Haematology. 168: 384-94. PMID 25303497 DOI: 10.1111/bjh.13146  0.8
2015 Wu Y, Hurren R, MacLean N, Gronda M, Jitkova Y, Sukhai MA, Minden MD, Schimmer AD. Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells Apoptosis. 20: 1099-1108. DOI: 10.1007/s10495-015-1137-x  0.8
2014 Kouznetsova J, Sun W, Martínez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, García-Sastre A. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerging Microbes & Infections. 3: e84. PMID 26038505 DOI: 10.1038/emi.2014.88  0.8
2014 Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. Plos One. 9: e108694. PMID 25285531 DOI: 10.1371/journal.pone.0108694  0.8
2014 Pandyra A, Mullen PJ, Kalkat M, Yu R, Pong JT, Li Z, Trudel S, Lang KS, Minden MD, Schimmer AD, Penn LZ. Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop. Cancer Research. 74: 4772-82. PMID 24994712 DOI: 10.1158/0008-5472.CAN-14-0130  0.8
2014 Jitkova Y, Gronda M, Hurren R, Wang X, Goard CA, Jhas B, Schimmer AD. A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. Plos One. 9: e95281. PMID 24871339 DOI: 10.1371/journal.pone.0095281  0.8
2014 Lee AY, St Onge RP, Proctor MJ, Wallace IM, Nile AH, Spagnuolo PA, Jitkova Y, Gronda M, Wu Y, Kim MK, Cheung-Ong K, Torres NP, Spear ED, Han MK, Schlecht U, ... ... Schimmer AD, et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science (New York, N.Y.). 344: 208-11. PMID 24723613 DOI: 10.1126/science.1250217  0.8
2014 Nissim R, Rodin G, Schimmer A, Minden M, Rydall A, Yuen D, Mischitelle A, Fitzgerald P, Lo C, Gagliese L, Zimmermann C. Finding new bearings: a qualitative study on the transition from inpatient to ambulatory care of patients with acute myeloid leukemia. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 22: 2435-43. PMID 24705856 DOI: 10.1007/s00520-014-2230-3  0.8
2014 Xu GW, Toth JI, da Silva SR, Paiva SL, Lukkarila JL, Hurren R, Maclean N, Sukhai MA, Bhattacharjee RN, Goard CA, Medeiros B, Gunning PT, Dhe-Paganon S, Petroski MD, Schimmer AD. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells. Plos One. 9: e93530. PMID 24691136 DOI: 10.1371/journal.pone.0093530  0.8
2014 Yee KW, Brandwein J, Schimmer AD, Gupta V, Del Bel R, Xu W, Minden MD, Schuh AC. Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation. British Journal of Haematology. 166: 303-6. PMID 24650042 DOI: 10.1111/bjh.12844  0.8
2014 Yip KW, Zhang Z, Sakemura-Nakatsugawa N, Huang JW, Vu NM, Chiang YK, Lin CL, Kwan JY, Yue S, Jitkova Y, To T, Zahedi P, Pai EF, Schimmer AD, Lovell JF, et al. A porphodimethene chemical inhibitor of uroporphyrinogen decarboxylase. Plos One. 9: e89889. PMID 24587102 DOI: 10.1371/journal.pone.0089889  0.8
2014 Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW, McLeod JL, Doedens M, Medeiros JJ, Marke R, Kim HJ, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 506: 328-33. PMID 24522528 DOI: 10.1038/nature13038  0.8
2014 Brandwein JM, Atenafu EG, Schuh AC, Yee KW, Schimmer AD, Gupta V, Minden MD. Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen. Leukemia Research. 38: 532-6. PMID 24444868 DOI: 10.1016/j.leukres.2013.10.025  0.8
2014 Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, ... ... Schimmer AD, et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. American Journal of Hematology. 89: 363-8. PMID 24273151 DOI: 10.1002/ajh.23640  0.8
2014 Goard CA, Schimmer AD. Mitochondrial matrix proteases as novel therapeutic targets in malignancy Oncogene. 33: 2690-2699. PMID 23770858 DOI: 10.1038/onc.2013.228  0.8
2013 Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A, Zacksenhaus E. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. Plos One. 8: e78641. PMID 24265703 DOI: 10.1371/journal.pone.0078641  0.8
2013 Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 98: 1896-904. PMID 24056819 DOI: 10.3324/haematol.2013.092411  0.8
2013 Martell MP, Atenafu EG, Minden MD, Schuh AC, Yee KW, Schimmer AD, Gupta V, Brandwein JM. Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol. British Journal of Haematology. 163: 458-64. PMID 24033272 DOI: 10.1111/bjh.12561  0.8
2013 Lenarduzzi M, Hui AB, Yue S, Ito E, Shi W, Williams J, Bruce J, Sakemura-Nakatsugawa N, Xu W, Schimmer A, Liu FF. Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer. Plos One. 8: e74075. PMID 23991213 DOI: 10.1371/journal.pone.0074075  0.8
2013 Page BD, Croucher DC, Li ZH, Haftchenary S, Jimenez-Zepeda VH, Atkinson J, Spagnuolo PA, Wong YL, Colaguori R, Lewis AM, Schimmer AD, Trudel S, Gunning PT. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. Journal of Medicinal Chemistry. 56: 7190-200. PMID 23968501 DOI: 10.1021/jm3017255  0.8
2013 Zhang J, Tang J, Cao B, Zhang Z, Li J, Schimmer AD, He S, Mao X. The natural pesticide dihydrorotenone induces human plasma cell apoptosis by triggering endoplasmic reticulum stress and activating p38 signaling pathway. Plos One. 8: e69911. PMID 23922854 DOI: 10.1371/journal.pone.0069911  0.8
2013 Zajdlik A, Wang Z, Hickey JL, Aman A, Schimmer AD, Yudin AK. α-Boryl isocyanides enable facile preparation of bioactive boropeptides. Angewandte Chemie (International Ed. in English). 52: 8411-5. PMID 23818141 DOI: 10.1002/anie.201302818  0.8
2013 Shahani VM, Ball DP, Ramos AV, Li Z, Spagnuolo PA, Haftchenary S, Schimmer AD, Trudel S, Gunning PT. A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. Bioorganic & Medicinal Chemistry. 21: 5618-28. PMID 23810672 DOI: 10.1016/j.bmc.2013.04.080  0.8
2013 Mourtada R, Fonseca SB, Wisnovsky SP, Pereira MP, Wang X, Hurren R, Parfitt J, Larsen L, Smith RA, Murphy MP, Schimmer AD, Kelley SO. Re-directing an alkylating agent to mitochondria alters drug target and cell death mechanism. Plos One. 8: e60253. PMID 23585833 DOI: 10.1371/journal.pone.0060253  0.8
2013 Jhas B, Sriskanthadevan S, Skrtic M, Sukhai MA, Voisin V, Jitkova Y, Gronda M, Hurren R, Laister RC, Bader GD, Minden MD, Schimmer AD. Metabolic adaptation to chronic inhibition of mitochondrial protein synthesis in acute myeloid leukemia cells. Plos One. 8: e58367. PMID 23520503 DOI: 10.1371/journal.pone.0058367  0.8
2013 Goard CA, Schimmer AD. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evidence. 8: 15-26. PMID 23515850 DOI: 10.2147/CE.S42568  0.8
2013 Zimmermann C, Yuen D, Mischitelle A, Minden MD, Brandwein JM, Schimmer A, Gagliese L, Lo C, Rydall A, Rodin G. Symptom burden and supportive care in patients with acute leukemia. Leukemia Research. 37: 731-6. PMID 23490030 DOI: 10.1016/j.leukres.2013.02.009  0.8
2013 Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH, Minden MD, Schimmer AD, Schuh AC, Yee KW, Gupta V. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood. 121: 2725-33. PMID 23361905 DOI: 10.1182/blood-2012-10-464248  0.8
2013 Hassanein M, Atenafu EG, Schuh AC, Yee KW, Minden MD, Schimmer AD, Gupta V, Brandwein JM. High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission. Leukemia Research. 37: 556-60. PMID 23357460 DOI: 10.1016/j.leukres.2013.01.001  0.8
2013 Nissim R, Zimmermann C, Minden M, Rydall A, Yuen D, Mischitelle A, Gagliese L, Schimmer A, Rodin G. Abducted by the illness: a qualitative study of traumatic stress in individuals with acute leukemia. Leukemia Research. 37: 496-502. PMID 23352641 DOI: 10.1016/j.leukres.2012.12.007  0.8
2013 Spagnuolo PA, Hurren R, Gronda M, Maclean N, Datti A, Basheer A, Lin FH, Wang X, Wrana J, Schimmer AD. Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity Leukemia. 27: 1236-1244. PMID 23318959 DOI: 10.1038/leu.2013.9  0.8
2013 Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne A, Cusimano M, Jhas B, Gronda M, MacLean N, Cho EE, ... ... Schimmer AD, et al. Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors Journal of Clinical Investigation. 123: 315-328. PMID 23202731 DOI: 10.1172/JCI64180  0.8
2013 Xu W, Lukkarila JL, da Silva SR, Paiva SL, Gunning PT, Schimmer AD. Targeting the ubiquitin E1 as a novel anti-cancer strategy. Current Pharmaceutical Design. 19: 3201-9. PMID 23151135 DOI: 10.2174/1381612811319180004  0.8
2013 Rodin G, Yuen D, Mischitelle A, Minden MD, Brandwein J, Schimmer A, Marmar C, Gagliese L, Lo C, Rydall A, Zimmermann C. Traumatic stress in acute leukemia. Psycho-Oncology. 22: 299-307. PMID 22081505 DOI: 10.1002/pon.2092  0.8
2013 How J, Sykes J, Minden MD, Gupta V, Yee KWL, Schimmer AD, Schuh AC, Kamel-Reid S, Brandwein JM. The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics Blood Cancer Journal. 3. DOI: 10.1038/bcj.2013.14  0.8
2012 Beheshti Zavareh R, Sukhai MA, Hurren R, Gronda M, Wang X, Simpson CD, Maclean N, Zih F, Ketela T, Swallow CJ, Moffat J, Rose DR, Schachter H, Schimmer AD, Dennis JW. Suppression of cancer progression by MGAT1 shRNA knockdown. Plos One. 7: e43721. PMID 22957033 DOI: 10.1371/journal.pone.0043721  0.8
2012 Liew E, Atenafu EG, Schimmer AD, Yee KW, Schuh AC, Minden MD, Gupta V, Brandwein JM. Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen. Leukemia Research. 36: 1517-20. PMID 22940259 DOI: 10.1016/j.leukres.2012.08.019  0.8
2012 Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B, Schimmer AD, Hedley DW. Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis. Plos One. 7: e41102. PMID 22829912 DOI: 10.1371/journal.pone.0041102  0.8
2012 Drewry JA, Duodu E, Mazouchi A, Spagnuolo P, Burger S, Gradinaru CC, Ayers P, Schimmer AD, Gunning PT. Phosphopeptide selective coordination complexes as promising SRC homology 2 domain mimetics. Inorganic Chemistry. 51: 8284-91. PMID 22784241 DOI: 10.1021/ic3008393  0.8
2012 How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia. Cancer. 118: 6110-7. PMID 22736495 DOI: 10.1002/cncr.27683  0.8
2012 Schimmer AD, Jitkova Y, Gronda M, Wang Z, Brandwein J, Chen C, Gupta V, Schuh A, Yee K, Chen J, Ackloo S, Booth T, Keays S, Minden MD. A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. Clinical Lymphoma, Myeloma & Leukemia. 12: 330-6. PMID 22683301 DOI: 10.1016/j.clml.2012.05.005  0.8
2012 Thyagu S, Minden MD, Gupta V, Yee KW, Schimmer AD, Schuh AC, Lipton JH, Messner HA, Xu W, Brandwein JM. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia with imatinib combined with a paediatric-based protocol. British Journal of Haematology. 158: 506-14. PMID 22650180 DOI: 10.1111/j.1365-2141.2012.09182.x  0.8
2012 Simpson CD, Hurren R, Kasimer D, MacLean N, Eberhard Y, Ketela T, Moffat J, Schimmer AD. A genome wide shRNA screen identifies α/β hydrolase domain containing 4 (ABHD4) as a novel regulator of anoikis resistance Apoptosis. 17: 666-678. PMID 22488300 DOI: 10.1007/s10495-012-0723-4  0.8
2012 Schimmer AD, Skrtić M. Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia. Expert Review of Hematology. 5: 117-9. PMID 22475277 DOI: 10.1586/ehm.12.8  0.8
2012 Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. Plos One. 7: e30215. PMID 22276160 DOI: 10.1371/journal.pone.0030215  0.8
2012 Saini L, Minden MD, Schuh AC, Yee KW, Schimmer AD, Gupta V, Atenafu EG, Murray C, Nixon S, Brandwein JM. Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia. American Journal of Hematology. 87: 323-6. PMID 22213349 DOI: 10.1002/ajh.22268  0.8
2012 de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, Chan ET, Kirk CJ, Peters GJ, Kruyt FA. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochemical Pharmacology. 83: 207-17. PMID 22027222 DOI: 10.1016/j.bcp.2011.10.009  0.8
2012 Franke NE, Niewerth D, Assaraf YG, van Meerloo J, Vojtekova K, van Zantwijk CH, Zweegman S, Chan ET, Kirk CJ, Geerke DP, Schimmer AD, Kaspers GJ, Jansen G, Cloos J. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia. 26: 757-68. PMID 21941364 DOI: 10.1038/leu.2011.256  0.8
2012 Caputo R, Calabrò ML, Micale N, Schimmer AD, Ali M, Zappalà M, Grasso S. Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents Medicinal Chemistry Research. 21: 2644-2651. DOI: 10.1007/s00044-011-9789-8  0.8
2012 Frail DE, Degennaro L, Schimmer A, Kasper J, Winneker R, Sherer TB, Urkowitz A, Dave KD, Panetta J, Mccall J. Drug Repositioning Efforts by Nonprofit Foundations Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs. 389-431. DOI: 10.1002/9781118274408.ch12  0.8
2011 Lukkarila JL, da Silva SR, Ali M, Shahani VM, Xu GW, Berman J, Roughton A, Dhe-Paganon S, Schimmer AD, Gunning PT. Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity. Acs Medicinal Chemistry Letters. 2: 577-82. PMID 24900352 DOI: 10.1021/ml2000615  0.8
2011 Skrti? M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, Hurren R, Jitkova Y, Gronda M, Maclean N, Lai CK, Eberhard Y, Bartoszko J, Spagnuolo P, Rutledge AC, ... ... Schimmer AD, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. 20: 674-88. PMID 22094260 DOI: 10.1016/j.ccr.2011.10.015  0.8
2011 Song S, Christova T, Perusini S, Alizadeh S, Bao RY, Miller BW, Hurren R, Jitkova Y, Gronda M, Isaac M, Joseph B, Subramaniam R, Aman A, Chau A, Hogge DE, ... ... Schimmer AD, et al. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Cancer Research. 71: 7628-39. PMID 22009536 DOI: 10.1158/0008-5472.CAN-11-2745  0.8
2011 Page BD, Fletcher S, Yue P, Li Z, Zhang X, Sharmeen S, Datti A, Wrana JL, Trudel S, Schimmer AD, Turkson J, Gunning PT. Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorganic & Medicinal Chemistry Letters. 21: 5605-9. PMID 21788134 DOI: 10.1016/j.bmcl.2011.06.056  0.8
2011 Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst HA, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, et al. Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study. Clinical Lymphoma, Myeloma & Leukemia. 11: 433-8. PMID 21729686 DOI: 10.1016/j.clml.2011.03.033  0.8
2011 Avadisian M, Fletcher S, Liu B, Zhao W, Yue P, Badali D, Xu W, Schimmer AD, Turkson J, Gradinaru CC, Gunning PT. Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept. Angewandte Chemie (International Ed. in English). 50: 6248-53. PMID 21721078 DOI: 10.1002/anie.201102486  0.8
2011 Fletcher S, Page BD, Zhang X, Yue P, Li ZH, Sharmeen S, Singh J, Zhao W, Schimmer AD, Trudel S, Turkson J, Gunning PT. Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules. Chemmedchem. 6: 1459-70. PMID 21618433 DOI: 10.1002/cmdc.201100194  0.8
2011 Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. Journal of the National Cancer Institute. 103: 1007-17. PMID 21606441 DOI: 10.1093/jnci/djr160  0.8
2011 Fonseca SB, Pereira MP, Mourtada R, Gronda M, Horton KL, Hurren R, Minden MD, Schimmer AD, Kelley SO. Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. Chemistry & Biology. 18: 445-53. PMID 21513881 DOI: 10.1016/j.chembiol.2011.02.010  0.8
2011 Sukhai MA, Spagnuolo PA, Weir S, Kasper J, Patton L, Schimmer AD. New sources of drugs for hematologic malignancies. Blood. 117: 6747-55. PMID 21511957 DOI: 10.1182/blood-2011-02-315283  0.8
2011 Wasylishen AR, Stojanova A, Oliveri S, Rust AC, Schimmer AD, Penn LZ. New model systems provide insights into Myc-induced transformation. Oncogene. 30: 3727-34. PMID 21441954 DOI: 10.1038/onc.2011.88  0.8
2011 Eberhard Y, Gronda M, Hurren R, Datti A, MacLean N, Ketela T, Moffat J, Wrana JL, Schimmer AD. Inhibition of SREBP1 sensitizes cells to death ligands Oncotarget. 2: 186-196. PMID 21406729  0.8
2011 Brandwein JM, Hedley DW, Chow S, Schimmer AD, Yee KWL, Schuh AC, Gupta V, Xu W, Kamel-Reid S, Minden MD. A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: Inhibition of Akt activation correlates with complete response Leukemia. 25: 945-952. PMID 21403650 DOI: 10.1038/leu.2011.34  0.8
2011 Weir SJ, Patton L, Castle K, Rajewski L, Kasper J, Schimmer AD. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. Journal of Clinical Pharmacy and Therapeutics. 36: 128-34. PMID 21366640 DOI: 10.1111/j.1365-2710.2010.01172.x  0.8
2011 Ito E, Yue S, Moriyama EH, Hui AB, Kim I, Shi W, Alajez NM, Bhogal N, Li G, Datti A, Schimmer AD, Wilson BC, Liu PP, Durocher D, Neel BG, et al. Uroporphyrinogen decarboxylase is a radiosensitizing target for head and neck cancer. Science Translational Medicine. 3: 67ra7. PMID 21270338 DOI: 10.1126/scitranslmed.3001922  0.8
2011 Schimmer AD. Clioquinol - A novel copper-dependent and independent proteasome inhibitor Current Cancer Drug Targets. 11: 325-331. PMID 21247386 DOI: 10.2174/156800911794519770  0.8
2011 Mao X, Hou T, Cao B, Wang W, Li Z, Chen S, Fei M, Hurren R, Gronda M, Wu D, Trudel S, Schimmer AD. The tricyclic antidepressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases: in vitro and in silico evidence. Molecular Pharmacology. 79: 672-80. PMID 21220410 DOI: 10.1124/mol.110.068122  0.8
2011 Shahani VM, Yue P, Fletcher S, Sharmeen S, Sukhai MA, Luu DP, Zhang X, Sun H, Zhao W, Schimmer AD, Turkson J, Gunning PT. Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein. Bioorganic & Medicinal Chemistry. 19: 1823-38. PMID 21216604 DOI: 10.1016/j.bmc.2010.12.010  0.8
2011 Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W, Spagnuolo PA, MacLean N, Moran MF, Datti A, Wrana J, ... ... Schimmer AD, et al. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood. 117: 1986-97. PMID 21135258 DOI: 10.1182/blood-2010-05-284810  0.8
2010 Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, Winton E, Verstovsek S. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clinical Lymphoma, Myeloma & Leukemia. 10: 285-9. PMID 20709666 DOI: 10.3816/CLML.2010.n.059  0.8
2010 Schimmer AD. Want fries with that? Antimyeloma drug combos. Blood. 116: 510-1. PMID 20671132 DOI: 10.1182/blood-2010-04-279927  0.8
2010 Sharmeen S, Skrtic M, Sukhai MA, Hurren R, Gronda M, Wang X, Fonseca SB, Sun H, Wood TE, Ward R, Minden MD, Batey RA, Datti A, Wrana J, Kelley SO, ... Schimmer AD, et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 116: 3593-603. PMID 20644115 DOI: 10.1182/blood-2010-01-262675  0.8
2010 Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, ... ... Schimmer AD, et al. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Journal of the National Cancer Institute. 102: 1069-82. PMID 20505154 DOI: 10.1093/jnci/djq198  0.8
2010 Tsao T, Kornblau S, Safe S, Watt JC, Ruvolo V, Chen W, Qiu Y, Coombes KR, Ju Z, Abdelrahim M, Schober W, Ling X, Kardassis D, Meyer C, Schimmer A, et al. Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia. Cancer Research. 70: 4949-60. PMID 20501850 DOI: 10.1158/0008-5472.CAN-09-1962  0.8
2010 Bacik JP, Walker JR, Ali M, Schimmer AD, Dhe-Paganon S. Crystal structure of the human ubiquitin-activating enzyme 5 (UBA5) bound to ATP: mechanistic insights into a minimalistic E1 enzyme. The Journal of Biological Chemistry. 285: 20273-80. PMID 20368332 DOI: 10.1074/jbc.M110.102921  0.8
2010 Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, Fine N, Simpson CD, Sharmeen S, Rottapel R, Schimmer AD. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood. 115: 4824-33. PMID 20348394 DOI: 10.1182/blood-2009-09-243055  0.8
2010 Drewry JA, Fletcher S, Yue P, Marushchak D, Zhao W, Sharmeen S, Zhang X, Schimmer AD, Gradinaru C, Turkson J, Gunning PT. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chemical Communications (Cambridge, England). 46: 892-4. PMID 20107641 DOI: 10.1039/b919608k  0.8
2010 Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, ... ... Schimmer AD, et al. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 115: 2251-9. PMID 20075161 DOI: 10.1182/blood-2009-07-231191  0.8
2010 Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, ... ... Schimmer AD, et al. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Molecular Cancer Therapeutics. 9: 246-56. PMID 20053768 DOI: 10.1158/1535-7163.MCT-09-0495  0.8
2010 Al-Khabori M, Minden MD, Yee KW, Gupta V, Schimmer AD, Schuh AC, Xu W, Brandwein JM. Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia. Leukemia & Lymphoma. 51: 61-5. PMID 20017600 DOI: 10.3109/10428190903388376  0.8
2010 Kohli R, Xu W, Brandwein J, Minden MD, Schimmer A, Schuh AC, Lipton JH, Yee K, Messner HA, Gupta V. Long-term outcomes in adult patients below the age of 55 years with acute lymphoblastic leukemia treated with chemotherapy or allogeneic BM transplant in first CR. Bone Marrow Transplantation. 45: 1256-8. PMID 19915631 DOI: 10.1038/bmt.2009.324  0.8
2009 Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO, Liu FF. Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Molecular Pharmacology. 76: 969-83. PMID 19654225 DOI: 10.1124/mol.109.055277  0.8
2009 Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4741-6. PMID 19652057 DOI: 10.1200/JCO.2009.21.8172  0.8
2009 Fletcher S, Singh J, Zhang X, Yue P, Page BD, Sharmeen S, Shahani VM, Zhao W, Schimmer AD, Turkson J, Gunning PT. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. Chembiochem : a European Journal of Chemical Biology. 10: 1959-64. PMID 19644994 DOI: 10.1002/cbic.200900172  0.8
2009 Eberhard Y, McDermott SP, Wang X, Gronda M, Venugopal A, Wood TE, Hurren R, Datti A, Batey RA, Wrana J, Antholine WE, Dick JE, Dick J, Schimmer AD. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. Blood. 114: 3064-73. PMID 19589922 DOI: 10.1182/blood-2009-03-209965  0.8
2009 Schimmer AD, Malkin D, Zackenhaus E, Kagal A, Klip A, Rotin D, Minden MD, Teitel J. Health care crisis in Gaza. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 180: 1230. PMID 19506287 DOI: 10.1503/cmaj.1090038  0.8
2009 Storring JM, Minden MD, Kao S, Gupta V, Schuh AC, Schimmer AD, Yee KW, Kamel-Reid S, Chang H, Lipton JH, Messner HA, Xu W, Brandwein JM. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. British Journal of Haematology. 146: 76-85. PMID 19438471 DOI: 10.1111/j.1365-2141.2009.07712.x  0.8
2009 Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X, Venugopal AL, Gronda M, Hurren R, Cheng S, Serra S, Beheshti Zavareh R, Datti A, Wrana JL, Ezzat S, Schimmer AD. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Research. 69: 2739-47. PMID 19293189 DOI: 10.1158/0008-5472.CAN-08-2530  0.8
2009 Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood. 113: 4027-37. PMID 19096011 DOI: 10.1182/blood-2008-09-179796  0.8
2009 Brandwein JM, Leber BF, Howson-Jan K, Schimmer AD, Schuh AC, Gupta V, Yee KWL, Wright J, Moore M, MacAlpine K, Minden MD. A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over Leukemia. 23: 631-634. PMID 19092853 DOI: 10.1038/leu.2008.341  0.8
2009 Ren X, Mao X, Cao L, Xue K, Si L, Qiu J, Schimmer AD, Li G. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 36: 401-11. PMID 19041719 DOI: 10.1016/j.ejps.2008.11.002  0.8
2009 Watanabe K, Ambekar C, Wang H, Ciccolini A, Schimmer AD, Dror Y. SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. Apoptosis : An International Journal On Programmed Cell Death. 14: 77-89. PMID 19009351 DOI: 10.1007/s10495-008-0275-9  0.8
2009 Mao X, Li X, Sprangers R, Wang X, Venugopal A, Wood T, Zhang Y, Kuntz DA, Coe E, Trudel S, Rose D, Batey RA, Kay LE, Schimmer AD. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia. 23: 585-90. PMID 18754030 DOI: 10.1038/leu.2008.232  0.8
2008 Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, Yee K, Ravandi F, Giles F, Schuh A, Gupta V, Andreeff M, Koller C, Chang H, Kamel-Reid S, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 8295-301. PMID 19088047 DOI: 10.1158/1078-0432.CCR-08-0999  0.8
2008 Kao SY, Xu W, Brandwein JM, Lipton JH, Messner HA, Minden MD, Schimmer AD, Schuh AC, Yee K, Gupta V. Outcomes of older patients (> or = 60 years) with acquired aplastic anaemia treated with immunosuppressive therapy. British Journal of Haematology. 143: 738-43. PMID 19062343 DOI: 10.1111/j.1365-2141.2008.07389.x  0.8
2008 Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Molecular Cancer Therapeutics. 7: 3546-55. PMID 19001437 DOI: 10.1158/1535-7163.MCT-08-0569  0.8
2008 Schimmer AD. Chemical biology--understanding biology and advancing therapy. Clinical and Investigative Medicine. MéDecine Clinique Et Experimentale. 31: E282-9. PMID 18980718  0.8
2008 Coe E, Schimmer AD. Catalase activity and arsenic sensitivity in acute leukemia. Leukemia & Lymphoma. 49: 1976-81. PMID 18949620 DOI: 10.1080/10428190802353617  0.8
2008 Mao X, Schimmer AD. The toxicology of Clioquinol. Toxicology Letters. 182: 1-6. PMID 18812216 DOI: 10.1016/j.toxlet.2008.08.015  0.8
2008 Beheshti Zavareh R, Lau KS, Hurren R, Datti A, Ashline DJ, Gronda M, Cheung P, Simpson CD, Liu W, Wasylishen AR, Boutros PC, Shi H, Vengopal A, Jurisica I, Penn LZ, ... ... Schimmer AD, et al. Inhibition of the sodium/potassium ATPase impairs N-glycan expression and function. Cancer Research. 68: 6688-97. PMID 18701493 DOI: 10.1158/0008-5472.CAN-07-6833  0.8
2008 Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Letters. 272: 177-85. PMID 18579285 DOI: 10.1016/j.canlet.2008.05.029  0.8
2008 Zhu X, Mao X, Hurren R, Schimmer AD, Ezzat S, Asa SL. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. The Journal of Clinical Endocrinology and Metabolism. 93: 3610-7. PMID 18544619 DOI: 10.1210/jc.2008-0578  0.8
2008 Sprangers R, Li X, Mao X, Rubinstein JL, Schimmer AD, Kay LE. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry. 47: 6727-34. PMID 18540636 DOI: 10.1021/bi8005913  0.8
2008 Mao X, Liang SB, Hurren R, Gronda M, Chow S, Xu GW, Wang X, Beheshti Zavareh R, Jamal N, Messner H, Hedley DW, Datti A, Wrana JL, Zhu Y, Shi CX, ... ... Schimmer AD, et al. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 112: 760-9. PMID 18502826 DOI: 10.1182/blood-2008-02-142687  0.8
2008 Ren X, Mao X, Si L, Cao L, Xiong H, Qiu J, Schimmer AD, Li G. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 70: 279-88. PMID 18499414 DOI: 10.1016/j.ejpb.2008.03.019  0.8
2008 Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, ... ... Schimmer AD, et al. Bcl-B expression in human epithelial and nonepithelial malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3011-21. PMID 18483366 DOI: 10.1158/1078-0432.CCR-07-1955  0.8
2008 Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. The Journal of Clinical Investigation. 118: 1750-64. PMID 18431519 DOI: 10.1172/JCI34149  0.8
2008 Katz D, Ito E, Lau KS, Mocanu JD, Bastianutto C, Schimmer AD, Liu FF. Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. Biotechniques. 44: ix-xiv. PMID 18422490 DOI: 10.2144/000112757  0.8
2008 Hurren R, Beheshti Zavareh R, Dalili S, Wood T, Rose D, Chang H, Jamal N, Messner H, Batey RA, Schimmer AD. A novel diquinolonium displays preclinical anti-cancer activity and induces caspase-independent cell death. Apoptosis : An International Journal On Programmed Cell Death. 13: 748-55. PMID 18415680 DOI: 10.1007/s10495-008-0209-6  0.8
2008 Schimmer AD. Apoptosis in leukemia: From molecular pathways to targeted therapies Best Practice and Research: Clinical Haematology. 21: 5-11. PMID 18342807 DOI: 10.1016/j.beha.2007.11.002  0.8
2008 Abdelhameed A, Pond GR, Mitsakakis N, Brandwein J, Chun K, Gupta V, Kamel-Reid S, Lipton JH, Minden MD, Schimmer A, Schuh A, Yee K, Messner HA. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation. Cancer. 112: 1513-21. PMID 18286528 DOI: 10.1002/cncr.23325  0.8
2008 Rujkijyanont P, Watanabe K, Ambekar C, Wang H, Schimmer A, Beyene J, Dror Y. SBDS-deficient cells undergo accelerated apoptosis through the Fas-pathway. Haematologica. 93: 363-71. PMID 18268284 DOI: 10.3324/haematol.11579  0.8
2008 Lourenco MT, Walsh A, Boon H, Al-Khabouri M, Brandwein J, Gupta V, Schuh A, Yee K, Rodin G, Schimmer AD. Superstition but not distrust in the medical system predicts the use of complementary and alternative medicine in a group of patients with acute leukemia [1] Leukemia and Lymphoma. 49: 339-341. PMID 18231922 DOI: 10.1080/10428190701742480  0.8
2008 Xu GW, Mawji IA, Macrae CJ, Koch CA, Datti A, Wrana JL, Dennis JW, Schimmer AD. A high-content chemical screen identifies ellipticine as a modulator of p53 nuclear localization. Apoptosis : An International Journal On Programmed Cell Death. 13: 413-22. PMID 18181020 DOI: 10.1007/s10495-007-0175-4  0.8
2008 Mao X, Zhu X, Hurren R, Ezzat S, Schimmer AD. Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells Leukemia Research. 32: 1480-1482. PMID 18177934 DOI: 10.1016/j.leukres.2007.11.031  0.8
2008 Brandwein JM, Gupta V, Schuh AC, Schimmer AD, Yee K, Xu W, Messner HA, Lipton JH, Minden MD. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. American Journal of Hematology. 83: 54-8. PMID 17696207 DOI: 10.1002/ajh.21034  0.8
2007 Schimmer AD. Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia Current Treatment Options in Oncology. 8: 277-286. PMID 18004514 DOI: 10.1007/s11864-007-0037-x  0.8
2007 Mao X, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, Shi C, Lee K, Tiedemann R, Eberhard Y, Trudel S, Liang S, Corey SJ, Gillis LC, Barber DL, ... ... Schimmer AD, et al. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 110: 4047-54. PMID 17875808 DOI: 10.1182/blood-2007-05-088666  0.8
2007 Mawji IA, Simpson CD, Gronda M, Williams MA, Hurren R, Henderson CJ, Datti A, Wrana JL, Schimmer AD. A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Research. 67: 8307-15. PMID 17804746 DOI: 10.1158/0008-5472.CAN-07-1687  0.8
2007 Disperati P, Minden MD, Gupta V, Schimmer AD, Schuh AC, Yee KW, Kamel-Reid S, Chang H, Xu W, Brandwein JM. Acute promyelocytic leukemia in patients aged 70 years and over -- a single center experience of unselected patients. Leukemia & Lymphoma. 48: 1654-8. PMID 17701604 DOI: 10.1080/10428190701472005  0.8
2007 Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA, Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas MP, Reed JC, Glinsky GV, Schimmer AD. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. Journal of the National Cancer Institute. 99: 811-22. PMID 17505076 DOI: 10.1093/jnci/djk182  0.8
2007 Gupta V, Xu W, Keng C, Alibhai SMH, Brandwein J, Schimmer A, Schuh A, Yee K, Minden MD. The outcome of intensive induction therapy in patients ≥70 years with acute myeloid leukemia [10] Leukemia. 21: 1321-1324. PMID 17344911 DOI: 10.1038/sj.leu.2404655  0.8
2007 Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, Messner HA, Gupta V, Chun K, Xu W, Das P, Kamel-Reid S, Brandwein JM. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leukemia & Lymphoma. 48: 65-71. PMID 17325849 DOI: 10.1080/10428190601043252  0.8
2007 Brandwein JM, Yang L, Schimmer AD, Schuh AC, Gupta V, Wells RA, Alibhai SMH, Xu W, Minden MD. A phase II study of temozolomide therapy for poor-risk patients aged ≥60 years with acute myeloid leukemia: Low levels of MGMT predict for response [9] Leukemia. 21: 821-824. PMID 17252015 DOI: 10.1038/sj.leu.2404545  0.8
2007 Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nature Reviews. Cancer. 7: 118-29. PMID 17251918 DOI: 10.1038/nrc2047  0.8
2007 Chang H, Schimmer AD. Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy Molecular Cancer Therapeutics. 6: 24-30. PMID 17237263 DOI: 10.1158/1535-7163.MCT-06-0443  0.8
2006 Schimmer AD. Induction of apoptosis in lymphoid and myeloid leukemia Current Oncology Reports. 8: 430-436. PMID 17040621 DOI: 10.1007/s11912-006-0071-z  0.8
2006 Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5557-69. PMID 17000693 DOI: 10.1158/1078-0432.CCR-06-0536  0.8
2006 Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Molecular Cancer Therapeutics. 5: 2234-40. PMID 16985057 DOI: 10.1158/1535-7163.MCT-06-0134  0.8
2006 Gurfinkel DM, Chow S, Hurren R, Gronda M, Henderson C, Berube C, Hedley DW, Schimmer AD. Disruption of the endoplasmic reticulum and increases in cytoplasmic calcium are early events in cell death induced by the natural triterpenoid Asiatic acid. Apoptosis : An International Journal On Programmed Cell Death. 11: 1463-71. PMID 16820960 DOI: 10.1007/s10495-006-9086-z  0.8
2006 Schimmer AD, Thomas MP, Hurren R, Gronda M, Pellecchia M, Pond GR, Konopleva M, Gurfinkel D, Mawji IA, Brown E, Reed JC. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Research. 66: 2367-75. PMID 16489043 DOI: 10.1158/0008-5472.CAN-05-1061  0.8
2006 Schimmer BP, Cordova M, Cheng H, Tsao A, Goryachev AB, Schimmer AD, Morris Q. Global profiles of gene expression induced by adrenocorticotropin in Y1 mouse adrenal cells. Endocrinology. 147: 2357-67. PMID 16484322 DOI: 10.1210/en.2005-1526  0.8
2006 Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death and Differentiation. 13: 179-88. PMID 16322751 DOI: 10.1038/sj.cdd.4401826  0.8
2005 Schimmer AD, Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 215-219. PMID 16304383  0.8
2005 Gronda M, Brandwein J, Minden MD, Pond GR, Schuh AC, Wells RA, Messner H, Chun K, Schimmer AD. Assessment of the downstream portion of the mitochondrial pathway of caspase activation in patients with acute myeloid leukemia Apoptosis. 10: 1285-1294. PMID 16215669 DOI: 10.1007/s10495-005-2764-4  0.8
2005 Brandwein JM, Gupta V, Wells RA, Schuh AC, Schimmer AD, Lipton JH, Messner HA, Yi QL, Chun K, Kamel-Reid S, Minden MD. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients. Leukemia Research. 29: 1381-6. PMID 15927253 DOI: 10.1016/j.leukres.2005.04.020  0.8
2005 Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, Glinsky GV. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells Cancer Research. 65: 2378-2386. PMID 15781653 DOI: 10.1158/0008-5472.CAN-04-2649  0.8
2005 Carter BZ, Gronda M, Wang Z, Welsh K, Pinilla C, Andreeff M, Schober WD, Nefzi A, Pond GR, Mawji IA, Houghten RA, Ostresh J, Brandwein J, Minden MD, Schuh AC, ... ... Schimmer AD, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells Blood. 105: 4043-4050. PMID 15687241 DOI: 10.1182/blood-2004-08-3168  0.8
2004 Schimmer AD. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice Cancer Research. 64: 7183-7190. PMID 15492230 DOI: 10.1158/0008-5472.CAN-04-1918  0.8
2004 Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Molecular Cancer Therapeutics. 3: 1239-48. PMID 15486191  0.8
2004 Wang Z, Cuddy M, Samuel T, Welsh K, Schimmer A, Hanaii F, Houghten R, Pinilla C, Reed JC. Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. The Journal of Biological Chemistry. 279: 48168-76. PMID 15337764 DOI: 10.1074/jbc.M405022200  0.8
2004 Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, Glinsky G, Scudiero D, Sausville E, Salvesen G, Nefzi A, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 5: 25-35. PMID 14749124 DOI: 10.1016/S1535-6108(03)00332-5  0.8
2003 Beanlands HJ, Lipton JH, McCay EA, Schimmer AD, Elliott ME, Messner HA, Devins GM. Self-concept as a "BMT patient", illness intrusiveness, and engulfment in allogeneic bone marrow transplant recipients. Journal of Psychosomatic Research. 55: 419-25. PMID 14581096 DOI: 10.1016/S0022-3999(03)00509-9  0.8
2003 Suh WS, Kim YS, Schimmer AD, Kitada S, Minden M, Andreeff M, Suh N, Sporn M, Reed JC. Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL Leukemia. 17: 2122-2129. PMID 12931220 DOI: 10.1038/sj.leu.2403112  0.8
2003 Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia Current Treatment Options in Oncology. 4: 211-218. PMID 12718798  0.8
2003 Schimmer AD, Pedersen IM, Kitada S, Eksioglu-Demiralp E, Minden MD, Pinto R, Mah K, Andreeff M, Kim Y, Suh WS, Reed JC. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Research. 63: 1242-8. PMID 12649183  0.8
2003 Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JH. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplantation. 31: 73-8. PMID 12621486 DOI: 10.1038/sj.bmt.1703790  0.8
2002 Pedersen IM, Kitada S, Schimmer A, Kim Y, Zapata JM, Charboneau L, Rassenti L, Andreeff M, Bennett F, Sporn MB, Liotta LD, Kipps TJ, Reed JC. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood. 100: 2965-72. PMID 12351409 DOI: 10.1182/blood-2002-04-1174  0.8
2002 Kitada S, Pedersen IM, Schimmer AD, Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies Oncogene. 21: 3459-3474. PMID 12032782 DOI: 10.1038/sj.onc.1205327  0.8
2002 Schimmer AD, Dranitsaris G, Ali V, Falconer M, Keating A. The autologous blood and marrow transplant long-term follow-up clinic: A model of care for following and treating survivors of autotransplant Supportive Care in Cancer. 10: 247-252. PMID 11904790 DOI: 10.1007/s00520-001-0316-1  0.8
2001 Schimmer AD, Elliott ME, Abbey SE, Raiz L, Keating A, Beanlands HJ, McCay E, Messner HA, Lipton JH, Devins GM. Illness intrusiveness among survivors of autologous blood and marrow transplantation. Cancer. 92: 3147-54. PMID 11753994 DOI: 10.1002/1097-0142(20011215)92:12<3147::AID-CNCR10168>3.0.CO;2-C  0.8
2001 Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view Blood. 98: 3541-3553. PMID 11739155 DOI: 10.1182/blood.V98.13.3541  0.8
2001 Schimmer AD, Hedley DW, Pham NA, Chow S, Minden MD. BAD induces apoptosis in cells over-expressing Bcl-2 of Bcl-xL without loss of mitochondrial membrane potential Leukemia and Lymphoma. 42: 429-443. PMID 11699408  0.8
2001 Schimmer AD, Mah K, Bordeleau L, Cheung A, Ali V, Falconer M, Trus M, Keating A. Decreased bone mineral density is common after autologous blood or marrow transplantation. Bone Marrow Transplantation. 28: 387-91. PMID 11571512 DOI: 10.1038/sj.bmt.1703149  0.8
2001 Schimmer AD, Hedley DW, Chow S, Pham NA, Chakrabartty A, Bouchard D, Mak TW, Trus MR, Minden MD. The BH3 domain of BAD fused to the Antennapedia peptide induces apoptosis via its alpha helical structure and independent of Bcl-2 Cell Death and Differentiation. 8: 725-733. PMID 11464217 DOI: 10.1038/sj.cdd.4400870  0.8
2001 Schimmer AD, Ali V, Stewart AK, Imrie K, Keating A. Male sexual function after autologous blood or marrow transplantation Biology of Blood and Marrow Transplantation. 7: 279-283. PMID 11400950  0.8
2000 Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L, Walker I, Benger A, Gluck S, Smith A. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada. Bone Marrow Transplantation. 26: 859-64. PMID 11081385 DOI: 10.1038/sj.bmt.1702625  0.8
2000 Schimmer AD, Minden MD, Keating A. Osteoporosis after Blood and Marrow Transplantation: Clinical Aspects Biology of Blood and Marrow Transplantation. 6: 175-181. PMID 10816025  0.8
1998 Schimmer A, Mody M, Sager M, Garvey MB, Hogarth M, Freedman J. Platelet cold agglutinins: a flow cytometric analysis. Transfusion Science. 19: 217-24. PMID 10351132 DOI: 10.1016/S0955-3886(98)00033-2  0.8
1998 Schimmer AD, Stewart AK, Keating A, MacKinnon J, Crump M, Sutton DM, Shepherd FA, Meharchand J. Safety of therapeutic anticoagulation in patients with multiple myeloma receiving autologous stem cell transplantation. Bone Marrow Transplantation. 22: 491-4. PMID 9733273 DOI: 10.1038/sj.bmt.1701363  0.8
1998 Schimmer AD, Quatermain M, Imrie K, Ali V, McCrae J, Stewart AK, Crump M, Derzko C, Keating A. Ovarian function after autologous bone marrow transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 2359-63. PMID 9667251  0.8
1998 Stewart AK, Schimmer AD, Bailey DJ, Dubé ID, Cappe D, Moen RC, Gauldie J, Graham FL. In vivo adenoviral-mediated gene transfer of interleukin-2 in cutaneous plasmacytoma. Blood. 91: 1095-7. PMID 9446678  0.8
Show low-probability matches.